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IMPORTANCE The role of aspirin as part of antiplatelet regimens in acute coronary syndromes
(ACS) needs to be clarified in the context of newer potent P2Y12 antagonists.
OBJECTIVE To evaluate the benefit and risks of aspirin in addition to ticagrelor among patients
with ACS beyond 1 month after percutaneous coronary intervention (PCI).
DESIGN, SETTING, AND PARTICIPANTS This is a nonprespecified, post hoc analysis of GLOBAL
LEADERS, a randomized, open-label superiority trial comparing 2 antiplatelet treatment
strategies after PCI. The trial included 130 secondary/tertiary care hospitals in different
countries, with 15 991 unselected patients with stable coronary artery disease or ACS
undergoing PCI. Patients had outpatient visits at 1, 3, 6, 12, 18, and 24 months after
index procedure.
INTERVENTIONS The experimental group received aspirin plus ticagrelor for 1 month
followed by 23-month ticagrelor monotherapy; the reference group received aspirin plus
either clopidogrel (stable coronary artery disease) or ticagrelor (ACS) for 12 months, followed
by 12-month aspirin monotherapy. In this analysis, we examined the clinical outcomes
occurring between 31 days and 365 days after randomization, specifically in patients with
ACS who, within this time frame, were assigned to receive either ticagrelor alone or ticagrelor
and aspirin.
MAIN OUTCOMES AND MEASURES The primary outcome was the composite of all-cause death
or new Q-wave myocardial infarction.
RESULTS Of 15 968 participants, there were 7487 patients with ACS enrolled; 3750 patients
were assigned to the experimental group and 3737 patients to the reference group. Between
31 and 365 days after randomization, the primary outcome occurred in 55 patients (1.5%) in
the experimental group and in 75 patients (2.0%) in the reference group (hazard ratio [HR],
0.73; 95% CI, 0.51-1.03; P = .07); investigator-reported Bleeding Academic Research
Consortium–defined bleeding type 3 or 5 occurred in 28 patients (0.8%) in the experimental
group and in 54 patients (1.5%) in the reference arm (HR, 0.52; 95% CI, 0.33-0.81; P = .004).
CONCLUSIONS AND RELEVANCE Between 1 month and 12 months after PCI in ACS, aspirin was
associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor
on ischemic events. These findings should be interpreted as exploratory and hypothesis
generating; however, they pave the way for further trials evaluating aspirin-free antiplatelet
strategies after PCI.
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T icagrelor in combination with aspirin more effec-tively reduced the rates of the composite end point ofcardiovascular death, myocardial infarction (MI), and
stroke compared with clopidogrel with aspirin among
patients presenting with acute coronary syndromes (ACS) in
the Study of Platelet Inhibition and Patient Outcomes
(PLATO) trial.1,2 Subgroup analyses revealed an interaction
between treatment benefit and geographic region, with a
suggestion of lower ticagrelor benefit in North American
patients.3 Although this interaction may have been a chance
finding, it was potentially attributable to an interaction
between ticagrelor and higher maintenance doses of aspirin
(≥300 mg).3 The latter were routinely used in North
America, and the lower benefit of ticagrelor appeared to
mirror the use of higher doses of aspirin in other geographi-
cal regions.3
Several experimental and small-scale clinical studies tried
to address this hypothesis further.3-7 Nevertheless, the effect
of aspirin and ticagrelor coadministration compared with
ticagrelor monotherapy has, to our knowledge, not yet been
explored in a large-scale patient cohort; the role of aspirin as
part of antiplatelet regimens, including more potent P2Y12
antagonists, needs to be further clarified.4
In the randomized GLOBAL LEADERS trial,5 ticagrelor with
aspirin for 1 month followed by ticagrelor alone for 23 months
was not significantly superior to 12 months of standard dual
antiplatelet therapy followed by 12 months of aspirin alone
in the prevention of the primary end point of all-cause death
or new Q-wave MI 2 years after percutaneous coronary inter-
vention (PCI) in an all-comer (stable coronary artery disease
or ACS) population.
Importantly, the study design and randomization scheme
provided the unique opportunity to explore the benefit of con-
tinuing aspirin in addition to ticagrelor in patients with ACS
beyond 1 month following PCI in a large-scale randomized
population.4,6 In this analysis, we examined the clinical out-
comes specifically in patients with ACS who, according to the
study protocol, between 31 and 365 days after randomization
received either ticagrelor alone or ticagrelor and aspirin at a
dose of 75 mg to 100 mg daily (Figure 1).
Methods
The GLOBAL LEADERS trial was a randomized, open-label
superiority trial conducted at 130 sites in 18 countries.5 The
formal trial protocols are in Supplement 1. The study design
and protocol have been previously described in detail6 and
are presented in the eAppendix in Supplement 2. Patients
undergoing PCI with a biolimus A9-eluting stent for stable
coronary artery disease or ACS were randomized to the
experimental treatment group receiving 75 mg to 100 mg
of aspirin daily plus 90 mg of ticagrelor twice daily for
1 month, followed by 23 months of ticagrelor monotherapy
or standard DAPT with 75 mg to 100 mg of aspirin daily plus
either 75 mg of clopidogrel daily (for patients with stable
coronary artery disease) or 90 mg of ticagrelor twice daily
(for patients with ACS) for 12 months, followed by 12-month
aspirin monotherapy. Randomization was concealed, strati-
fied by center and clinical presentation (stable coronary
artery disease vs ACS), and blocked, with randomly varied
block sizes of 2 and 4.6 The GLOBAL LEADERS study was
approved by the institutional review board at each partici-
pating center. All patients provided written informed con-
sent. The study complied with the Declaration of Helsinki
and Good Clinical Practices.
Key Points
Question What are the benefits and risks of continuing aspirin
in addition to P2Y12 receptor inhibition with ticagrelor among
patients with acute coronary syndrome between 1 month and
12 months after percutaneous coronary intervention?
Findings In this nonprespecified, post hoc analysis of the
GLOBAL LEADERS randomized clinical trial, beyond 1 month after
percutaneous coronary intervention in acute coronary syndrome,
aspirin was associated with increased bleeding risk and appeared
not to add to the benefit of ticagrelor on ischemic events.
Meaning The findings of this hypothesis-generating analysis pave
the way for further trials evaluating aspirin-free antiplatelet
strategies after percutaneous coronary intervention.
Figure 1. Study Design, Patient Population, and Randomized Treatment in the GLOBAL LEADERS Trial
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In this investigation, we evaluated the
clinical outcomes specifically in
patients with acute coronary
syndrome (ACS) who, according to
the study protocol, between 31 and
365 days after randomization were to
receive either ticagrelor alone or
ticagrelor and aspirin (ASA) at a
dose of 75 mg to 100 mg daily.
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The primary outcome was a composite of all-cause mor-
tality or new nonfatal, centrally adjudicated Q-wave MI at 2
years (eAppendix in Supplement 2). The key secondary safety
outcome was site-reported bleeding assessed according to the
Bleeding Academic Research Consortium (BARC) criteria (type
3 or 5). Secondary site–reported clinical outcomes included
all-cause death, cardiovascular death, stroke, site-reported MI
(according to the Third Universal Definition), revasculariza-
tion including target vessel revascularization (TVR), definite
stent thrombosis, and the composite end point of death, MI,
stroke, or BARC type 3 or 5 bleeding at 2 years. In addition, we
evaluated the rates of the Academic Research Consortium
2–defined patient-oriented composite end points (POCE:
all-cause mortality, any stroke, MI, or revascularization) and
net-adverse clinical events (NACE: POCE or BARC type 3 or 5
bleeding).7,8
Sample size considerations, the primary end point analy-
ses, and the results of formal interaction testing on
treatment-by-clinical presentation interaction (ACS vs stable
CAD subgroups) with regard to the primary end point and
BARC 3 or 5 type bleeding events up to 2 years have been
described previously.5,6 In this investigation, analyses of
events occurring between the 2 prespecified landmark points
in the GLOBAL LEADERS design, 31 days and 365 days of
follow-up, were performed in patients with ACS who were
alive at 31 days and did not encounter events of the specific
type nor were censored prior to this landmark. Analyses were
conducted following the intention-to-treat definition using
the Mantel-Cox log-rank method up to the point when the
first event occurred. Hazard ratios (HR) with 95% confidence
intervals were reported. In addition, we performed sensitiv-
ity analyses among (1) patients with ACS who remained
adherent to the randomized treatment, as assessed at each of
the prespecified follow-up visits (at 1 month, 30 days, 90
days, 180 days, and 365 days), and (2) among patients with
ACS who underwent complex PCI, defined according to the
previously described definitions.9,10
Analyses were performed with SPSS, version 25 (IBM Corp).
A 2-sided P value of less than .05 was considered statistically
significant. No adjustments were made for multiple compari-
sons, and therefore all presented results should be viewed as
only hypothesis generating.
Results
Of 15 968 participants randomized between July 1, 2013, and
November 9, 2015, there were 7487 patients with ACS; 3750
patients had been assigned to the experimental group and
3737 patients to the reference group. Baseline characteristics
were well balanced between groups (Table 1; eTable 1 in
Supplement 2).
Thirty days after PCI, the rates of the primary outcome (22
patients [0.6%] vs 28 patients [0.7%]; HR, 0.78; 95% CI, 0.45-
1.37; P = .39) and key safety outcome of BARC type 3 or 5 bleed-
ing (29 patients [0.8%] vs 34 patients [0.9%]; HR, 0.85; 95%








Age >75 y 548 (14.7) 558 (14.9) .79
Female 854 (22.9) 870 (23.2) .72
Acute coronary syndrome type
Unstable angina 1018 (27.2) 1004 (26.8)
.75NSTEMI 1689 (45.2) 1684 (44.9)
STEMI 1030 (27.6) 1062 (28.3)
Geographic area
West Europe 2825 (75.6) 2879 (76.8)
.48East Europe 793 (21.2) 755 (20.1)
Rest of the world 119 (3.2) 116 (3.1)
Diabetes 795 (21.3) 809 (21.6) .74
Insulin-dependent diabetes 243 (6.5) 208 (5.6) .09
Hypertension 2523 (67.9) 2560 (68.6) .48
Hypercholesterolemia 2211 (62.0) 2178 (60.8) .33
Previous stroke more than 30 d ago 94 (2.5) 81 (2.2) .31
Previous myocardial infarction 695 (18.6) 685 (18.3) .72
Previous percutaneous coronary intervention 872 (23.4) 854 (22.8) .55
Previous coronary artery bypass grafting 145 (3.9) 130 (3.5) .34
Peripheral vascular disease 196 (5.3) 191 (5.1) .77
Chronic obstructive pulmonary disease 177 (4.8) 174 (4.7) .85
Previous major bleeding 24 (0.6) 24 (0.6) .99
Current smoking 1255 (33.6) 1288 (34.3) .49
Impaired renal functiona 467 (12.5) 500 (13.4) .27
Abbreviations: NSTEMI, non–ST
segment elevation myocardial
infarction; STEMI, ST segment
elevation myocardial infarction.
a Estimated glomerular filtration rate
of creatinine clearance of less than
60 mL/min per 1.73 m2 based on the
Modification of Diet in Renal
Disease Formula.
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CI, 0.52-1.40; P = .52) did not differ significantly between
the experimental and the reference arm (eTable 2 in
Supplement).
Between 31 days and 365 days after randomization, the pri-
mary outcome occurred in 55 patients (1.5%) and 75 patients
(2.0%) in the experimental and reference groups, respec-
tively (HR, 0.73; 95% CI, 0.51-1.03; P = .07); BARC type 3 or 5
bleeding occurred in 28 patients (0.8%) in the experimental
arm and in 54 patients (1.5%) in the reference arm (HR, 0.52;
95% CI, 0.33-0.81; P = .004) (Table 2, Figure 2; eFigures 1 and
2 in Supplement 2). No differences in the rates of all-cause
death, any stroke (hemorrhagic or ischemic), any MI, revas-
cularizations, including TVR, definite stent thrombosis, POCE,
or NACE, were observed between 31 days and 365 days in both
treatment groups.
The composite end point of all-cause death, stroke, site-
reported MI, and BARC type 3 or 5 bleeding occurred in 117
patients (3.2%) in the experimental arm and in 148 patients
(4.1%) in the reference arm (HR, 0.79; 95% CI, 0.62-1.00;
P = .05). The additional bleeding outcomes occurring be-
tween 31 days and 365 days have been presented in eTable 3
in Supplement 2 and Figure 3. The cumulative 1-year event rates
have been presented in eTable 4 in Supplement 2. At 1 year
after PCI, the rates of the primary outcome (77 patients [2.1%]
vs 103 patients [2.8%]; HR, 0.74; 95% CI, 0.55-1.00; P = .05)
did not differ significantly between the 2 groups; the rates of
key safety outcome of BARC type 3 or 5 bleeding (57 patients
[1.5%] vs 88 patients [2.4%]; HR, 0.64; 95% CI, 0.46-0.90;
P = .009) were lower in the experimental group compared with
the reference group.
The adherence to the randomized treatment in the experi-
mental vs the reference arm was 97.0% vs 95.1%, 86.9% vs
87.7%, and 84.1% vs 85.2% at 1, 6, and 12 months, respec-
tively. A sensitivity analysis in patients who adhered to the
randomized treatment, as assessed at each follow-up visit
between discharge and 365 days, indicated lower rates of site-
reported MI, any revascularizations, TVR, POCE, NACE, and
the composite end point of cardiac death, site-reported MI, and
stroke in the experimental arm compared with the reference
arm, which was associated with consistently lower, although
not statistically different, rates of BARC 3 type bleeding
(eTable 5 in Supplement 2). A sensitivity analysis in patients
with ACS who underwent complex PCI (n = 2221) showed lower
rates of the primary outcome, all-cause death, BARC 3 and
BARC 3 or 5 type bleeding, and the composite end point of
cardiac death, site-reported MI, and stroke between 31 days
and 365 days in the experimental vs the reference group
(eTables 6-8 and eFigure 3 in Supplement 2).
Table 2. Clinical Events In Patients With Acute Coronary Syndrome Between 31 Days and 365 Daysa,b
Event
No. of Events/No. of Patients at Risk (%)





Primary outcome: all-cause death
or new Q-wave MI
75/3708 (2.0) 55/3728 (1.5) 0.73 (0.51-1.03) .07
Key safety outcome:
BARC 3 or 5 bleeding
54/3666 (1.5) 28/3680 (0.8) 0.52 (0.33-0.81) .004
BARC 3 bleeding 53/3666 (1.5) 27/3680 (0.7) 0.51 (0.32-0.80) .003
BARC 3a bleeding 25/3683 (0.7) 13/3690 (0.4) 0.52 (0.27-1.01) .06
BARC 3b bleeding 24/3681 (0.7) 9/3693 (0.2) 0.37 (0.17-0.81) .01
BARC 3c bleeding 6/3690 (0.27) 7/3702 (0.19) 1.16 (0.39-3.46) .79
BARC 5 bleeding 4/3695 (0.11) 2/3703 (0.05) 0.50 (0.09-2.73) .41
BARC 5a bleeding 2/3695 (0.05) 1/3703 (0.03) 0.50 (0.05-5.51) .57
BARC 5b bleeding 2/3695 (0.05) 1/3703 (0.03) 0.50 (0.05-5.51) .57
All-cause death 51/3712 (1.4) 38/3729 (1.0) 0.74 (0.49-1.13) .16
New Q-wave MI 25/3708 (0.7) 17/3728 (0.5) 0.68 (0.37-1.25) .21
Strokec 14/3683 (0.4) 17/3697 (0.5) 1.21 (0.60-2.46) .59
Ischemic 12/3685 (0.3) 13/3697 (0.4) 1.08 (0.49-2.37) .84
Hemorrhagic 2/3694 (0.1) 3/3703 (0.1) 1.50 (0.25-8.96) .66
Undetermined 0/3694 1/3703 (0.03) NA NA
MI (site-reported) 52/3660 (1.4) 50/3660 (1.4) 0.96 (0.65-1.42) .85
Revascularization 172/3615 (4.8) 181/3642 (5.0) 1.05 (0.85-1.29) .66
TVR 96/3644 (2.6) 84/3664 (2.3) 0.87 (0.65-1.17) .36
Definite ST 6/3679 (0.2) 7/3679 (0.2) 1.17 (0.39-3.47) .78
Composite end points
Death, new Q-wave MI, stroke 85/3680 (2.3) 67/3697 (1.8) 0.79 (0.57-1.08) .14
Cardiac death, MI, stroke 81/3648 (2.2) 80/3654 (2.2) 0.99 (0.73-1.35) .94
POCE 229/3591 (6.4) 231/3621 (6.4) 1.00 (0.84-1.21) .97
Death, MI, stroke,
or BARC 3/5 bleeding
148/3622 (4.1) 117/3633 (3.2) 0.79 (0.62-1.00) .05
NACE 266/3564 (7.5) 248/3600 (6.9) 0.92 (0.78-1.10) .36
Abbreviations: BARC, Bleeding
Academic Research Consortium;
HR, hazard ratio; NACE, net adverse
clinical events; MI, myocardial
infarction; NA, not applicable;
POCE, patient-oriented composite
end points; ST, stent thrombosis;
TVR, target vessel revascularization.
a The primary outcome was a
composite of all-cause mortality or
nonfatal, centrally adjudicated, new
Q-wave MI. Patient-oriented
composite end point included
all-cause mortality, any stroke, MI,
or revascularization, whereas NACE
comprised POCE or BARC 3 or 5
type bleeding. P values were for the
log-rank test.
b In these time frames, experimental
regimen is ticagrelor monotherapy
and reference regimen is ticagrelor
plus aspirin.
c Not including transient ischemic
attack.
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Discussion
For the first time to our knowledge, the role of aspirin com-
bined with the potent P2Y12 inhibitor ticagrelor has been spe-
cifically evaluated in a large ACS trial population undergoing
PCI. The salient findings from this post hoc landmark analy-
sis can be summarized as follows:
1. There was no evidence of a benefit to continue aspirin in
addition to ticagrelor between 1 month and 1 year after PCI
in patients with ACS with respect to the rates of all-cause
death or new Q-wave MI.
2. Continuation of aspirin, in addition to ticagrelor, was asso-
ciated with a significant increase in the key safety end point
of BARC type 3 or 5 bleeding.
These findings need to be interpreted cautiously because
the presented analyses were not prespecified and the trial did
not meet its primary end point.5,6 The observed event rates in
GLOBAL LEADERS were lower than anticipated; all presently
reported relative risk differences need also to be viewed in the
light of small absolute differences in event rates.5,6 Notwith-
standing this limitation, the observation of the absence of
significant difference in the rates of the primary end point of
all-cause death or new Q-wave MI beyond 1 month after PCI
in patients with ACS receiving solely ticagrelor is noteworthy
because this challenges the additive effect of combining aspi-
rin with ticagrelor for secondary prevention of ischemic events
after the initial 30 days following PCI. Putatively, based on nu-
merically lower rates of the primary end point that in our study
consisted of 2 ischemic components, one may suspect that the
adverse interaction between ticagrelor and aspirin, previ-
ously suggested for higher doses of aspirin (> 150 mg), may be
also present when aspirin is administered at lower doses
(75 mg-100 mg).3,11
Aspirin is widely used in secondary prevention of
atherosclerotic disease; however, there is some geographical
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30 d 365 d
All-cause mortality (A), Bleeding Academic Research Consortium
(BARC)–defined bleeding type 3 or 5 (B), patient-oriented composite end points
(POCE) (C), and net-adverse clinical events (NACE) (D). Patient-oriented
composite endpoint (POCE) included all-cause mortality or any stroke,
myocardial infarction, or revascularization, whereas net-adverse clinical events
(NACE) comprised POCE and BARC type 3 or 5 bleeding. Patients who were
alive at 31 days of follow-up and did not encounter event of the specific type nor
were censored prior to the landmark of 30 days have been included in this
analysis. HR indicates hazard ratio.
a In these time frames, according to the study protocol, the experimental
regimen is ticagrelor monotherapy and the reference regimen is ticagrelor
plus aspirin.
Research Original Investigation Benefit and Risks of Aspirin on Top of Ticagrelor in Acute Coronary Syndromes
1096 JAMA Cardiology November 2019 Volume 4, Number 11 (Reprinted) jamacardiology.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of Szeged User  on 01/22/2020
variation in the dose used, varying from 50 mg to more than
300 mg.3 Importantly, the number of prospective studies
addressing the association of aspirin dose with clinical out-
come in patients with ACS is still limited.11 The considered
magnitude of aspirin benefit for patients with ACS and its
very low cost has resulted in all other antiplatelet agents
being tested on top of aspirin, with the assumption of addi-
tive effects of both medications. Nevertheless, in light of the
central role of the P2Y12 signaling pathway on platelet acti-
vation and amplification processes, potent P2Y12 blockade
can also lead to downregulation of other markers of platelet
reactivity, including arachidonic acid-induced and collagen-
induced aggregation.4,12,13
Biologically, it has been hypothesized that in the pres-
ence of potent P2Y12 inhibitors, aspirin adds little additional
inhibition of platelet aggregation mediated by thromboxane
A2, while potentially having detrimental effects resulting
from inhibition of the formation of prostaglandins such as
prostanglandin I2 (prostacyclin).14,15 Prostanglandin I2 inhib-
its platelet aggregation and induces vasodilation; thus, theo-
retically, more profound suppression of PGI2 formation as a
function of dose-dependent inhibition of cyclooxygenase-2
by high doses of aspirin could attenuate the antithrombotic
effect of aspirin and potentially predispose to thrombosis.
Such a phenomenon has been previously demonstrated for
selective cyclooxygenase-2 inhibitors and other nonsteroidal
anti-inflammatory drugs.14,15 Yet aspirin still yields additive
inhibition of arachidonic acid-induced and collagen-induced
platelet aggregation, even in the presence of potent P2Y12
inhibition.11,16 Moreover, investigations have shown that
high-dose aspirin does not interfere with the pharmacoki-
netic or pharmacodynamic effects of ticagrelor, and aspirin
dosing does not modulate pharmacodynamic markers of
P2Y12 signaling irrespective of the degree of P2Y12 receptor
blockade.12,13 Therefore, the question remains as to whether
the additive value of aspirin mediated through inhibition of
TXA2-mediated platelet aggregation is offset by the inhibi-
tion of prostacyclin synthesis in vivo, which is generally not
accurately assessed by laboratory studies.11-13 Consequently,
the clinical data from prospective studies of aspirin in com-
bination therapy have been eagerly awaited,11 underscoring
the incremental value of this report from a large randomized
study to the understanding of ticagrelor and aspirin interac-
tion among patients with ACS.
Previously, the CURRENT OASIS 7 trial17 compared differ-
ent dose ranges of aspirin on clinical outcomes, but this was
always in a combination with a P2Y12 antagonist, clopido-
grel. Of note, neither the primary composite end point of
cardiovascular mortality, MI, or stroke (HR, 0.97; 95% CI, 0.86-
1.09; P = .61) nor major bleeding events (HR, 0.99; 95% CI, 0.84-
1.17; P = .90) were identified to be different in patients treated
with higher or lower doses of aspirin. However, patients re-
ceiving higher doses of aspirin had a higher rate of gastro-
intestinal bleeding (0.4% vs 0.2%; P = .04).17
In the CAPRIE study,18 there were fewer ischemic events
observed in patients treated with a less potent P2Y12 receptor
antagonist, clopidogrel, than in patients receiving aspirin, and
a lower rate of gastrointestinal bleeding was found in clopido-
grel group, likely owing to aspirin’s unfavorable local gastro-
intestinal bleeding effect. In that context, one may suspect even
better efficacy and safety of ticagrelor monotherapy given its
superior potency and specificity in P2Y12 receptor inhibition.
Between 31 days and 365 days after randomization, simi-
lar rates (2.2% vs 2.2%) of the composite end points of site-
reported cardiovascular mortality, MI, or stroke were ob-
served in both treatment groups among patients with ACS from
the GLOBAL LEADERS trial (HR, 0.99; 95% CI, 0.73-1.35). How-
ever, these rates were lower than the rates of the composite
end point of cardiovascular mortality, MI, or stroke occurring
between 31 days and 365 days in either ticagrelor or clopido-
Figure 3. Bleeding Academic Research Consortium (BARC)–Defined Bleeding Events Type 2 (A) and Type 3 (B) Between 31 and 365 Days
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a In these time frames, according to the study protocol, the experimental regimen is ticagrelor monotherapy and the reference regimen is ticagrelor
plus aspirin.
HR indicates hazard ratio.
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grel arm of the PLATO study1 (5.3% vs 6.6%, respectively; HR,
0.80; 95% CI, 0.70-0.91; P = .001).1 This may be related to the
lower risk of patient clinical profile in the GLOBAL LEADERS
study compared with the PLATO study patients.1
Notably, this analysis indicated an excess in bleeding risk
associated with aspirin use beyond 1 month and up to 1 year
after PCI. Such increase in bleeding risk needs also to be con-
sidered with its negative effect on treatment adherence, po-
tentially leading to higher rates of ischemic events and mor-
tality. Nevertheless, this relevant observation needs to be
confirmed in dedicated clinical trials before any change to clini-
cal practice can be recommended.19 The ongoing TWILIGHT
trial19 is addressing a relatively similar hypothesis to GLOBAL
LEADERS, with aspirin withdrawal on a background of ticagre-
lor at 3 months after PCI in high-risk patients defined accord-
ing to prespecified clinical and anatomical criteria. In con-
trast to the GLOBAL LEADERS study, TWILIGHT has selected
bleeding BARC 2, 3, or 5 type as the composite primary end
point for the superiority analysis and the composite second-
ary end point of ischemic events (all-cause death, nonfatal MI,
or stroke) for the noninferiority analysis.
Whereas sole use of ticagrelor following 1 month after PCI
in the ACS setting appears a promising strategy for improving
net clinical benefit, it also cannot be excluded that new aspi-
rin formulations reportedly associated with predictable anti-
platelet efficacy and improved gastrointestinal safety may
result in improved clinical performance compared with tradi-
tionally used enteric-coated aspirin formulations.20,21
Limitations
This report has to be viewed in light of the following limita-
tions: it is a post hoc exploratory additional landmark analy-
sis, not prespecified in the GLOBAL LEADERS study protocol.
The GLOBAL LEADERS trial was neutral in the primary end
point analysis in the overall population, and the presented sec-
ondary analysis, as in the parent trial, was not powered to
detect between-group differences in clinical outcomes.
Because the goal of this investigation was to explore the
synergies between aspirin and ticagrelor (with a minimized
confounding effect of other antiplatelet P2Y12 antagonists), we
selected only the patients with ACS because the patients
presenting with stable CAD largely received clopidogrel as a
reference treatment in this study.5 The formal subgroup analy-
sis among patients with ACS vs patients with stable CAD, with
interaction tests for the primary end point and BARC 3 or 5 type
bleeding, has been described previously.5 While the analysis
of the event rates occurring between 31 days and 365 days
enables comparisons in 2 groups receiving homogenous
antiplatelet regimens (ticagrelor alone or ticagrelor and aspi-
rin), landmark analyses at 30 days affect the balance estab-
lished by randomization. Nevertheless, no significant differ-
ences were found in the baseline characteristics between
treatment groups among the selected patients that were in-
cluded in the landmark analysis.
All the presented findings must be interpreted strictly as
hypothesis generating. Event rates in both arms were low
compared with the PLATO study and so it is uncertain
whether ticagrelor monotherapy will provide sufficient effi-
cacy in patients at high risk of ischemic events. Neverthe-
less, the exploratory sensitivity analyses performed in
patients who adhered to the randomized treatment and in
patients who underwent complex PCI procedures indicated
consistent results in these subsets. The prespecified sub-
analysis on treatment-by-clinical-presentation (ACS vs stable
CAD) interaction in the overall study cohort, with formal
interaction tests for treatment effects on 2-year secondary
clinical outcomes, will be presented and discussed in a
stand-alone manuscript.
Finally, investigator reporting was used without central ad-
judication for secondary outcomes.6 Therefore, bias and ran-
dom event misclassification cannot be excluded. This limita-
tion should be considered in particular when interpreting
bleeding event rates. However, the trial was monitored for
event definition consistency and event underreporting, with
as many as 7 onsite monitoring visits done at individual sites
and one-fifth of events verified based on the source documen-
tation. Use of site-reported end points is a valid method in clini-
cal research, especially involving large cohorts and well-
defined and restricted categories within a classification (eg,
BARC-defined bleeding type 3 to 5 as compared with type 1 and
2) are expected to provide higher concordance among sites
and a central clinical event adjudication committee, as well as
higher reproducibility.
Conclusions
Between 1 month and 12 months after PCI in ACS, aspirin was
associated with increased bleeding risk and appeared not to
add to the benefit of ticagrelor in the prevention of ischemic
outcomes. These findings should be interpreted as explor-
atory and hypothesis generating. However, they pave the way
for further trials evaluating aspirin-free antiplatelet strate-
gies after PCI.
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